Angiogenesis in life, disease and medicine

Ny, A. et al. A genetic Xenopus laevis tadpole model to study lymphangiogenesis. Nature Med. 11, 998–1004 (2005).

Carmeliet, P. Angiogenesis in health and disease. Nature Med. 9, 653–660 (2003).

Carmeliet, P. & Tessier-Lavigne, M. Common mechanisms of nerve and blood vessel wiring. Nature 436, 193–200 (2005).

Lambrechts, D., Storkebaum, E. & Carmeliet, P. VEGF: necessary to prevent motoneuron degeneration, sufficient to treat ALS? Trends Mol. Med. 10, 275–282 (2004).

Luttun, A., Autiero, M., Tjwa, M. & Carmeliet, P. Genetic dissection of tumor angiogenesis: are PlGF and VEGFR-1 novel anti-cancer targets? Biochim. Biophys. Acta 1654, 79–94 (2004).

Simons, M. Angiogenesis: where do we stand now? Circulation 111, 1556–1566 (2005).

Jain, R. K., Duda, D. G., Clark, J. W. & Loeffler, J. S. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nature Clin. Pract. Oncol. (in the press).

Jain, R. K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307, 58–62 (2005).

Kerbel, R. S. & Kamen, B. A. The anti-angiogenic basis of metronomic chemotherapy. Nature Rev. Cancer 4, 423–436 (2004).

Ostman, A. PDGF receptors—mediators of autocrine tumor growth and regulators of tumor vasculature and stroma. Cytokine Growth Factor Rev. 15, 275–286 (2004).

Song, S., Ewald, A. J., Stallcup, W., Werb, Z. & Bergers, G. PDGFRβ+ perivascular progenitor cells in tumours regulate pericyte differentiation and vascular survival. Nature Cell Biol. 7, 870–879 (2005).

Bergers, G., Song, S., Meyer-Morse, N., Bergsland, E. & Hanahan, D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J. Clin. Invest. 111, 1287–1295 (2003).

Heldin, C. H., Rubin, K., Pietras, K. & Ostman, A. High interstitial fluid pressure — an obstacle in cancer therapy. Nature Rev. Cancer 4, 806–813 (2004).

Orimo, A. et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 121, 335–348 (2005).

Buttery, R. C., Rintoul, R. C. & Sethi, T. Small cell lung cancer: the importance of the extracellular matrix. Int. J. Biochem. Cell Biol. 36, 1154–1160 (2004).

Coussens, L. M. & Werb, Z. Inflammation and cancer. Nature 420, 860–867 (2002).

De Palma, M. et al. Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell 8, 211–226(2005).

Takakura, N. et al. A role for hematopoietic stem cells in promoting angiogenesis. Cell 102, 199–209 (2000).

Rafii, S. & Lyden, D. Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration. Nature Med. 9, 702–712 (2003).

Grunewald, M. et al. VEGF-induced adult neovascularization depends on SDF-1-mediated retention of bone marrow derived accessory cells. Cell (in the press).

Kaplan, R. N. et al. VEGFR1-positive hematopoietic bone marrow progenitors initiate the premestatic niche. Nature 438, 820–827 (2005).

Zou, W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nature Rev. Cancer 5, 263–274 (2005).

Izumi, Y., Xu, L., di Tomaso, E., Fukumura, D. & Jain, R. K. Tumour biology: Herceptin acts as an anti-angiogenic cocktail. Nature 416, 279–280 (2002).

Hirakawa, S. et al. VEGF-A induces tumor and sentinel lymph node lymphangiogenesis and promotes lymphatic metastasis. J. Exp. Med. 201, 1089–1099 (2005).

Fletcher, J. A. Role of KIT and platelet-derived growth factor receptors as oncoproteins. Semin. Oncol. 31, 4–11 (2004).

Gilbert, S. F. Developmental Biology, 6th edn (Swarthmore College, Sinauer Assoc., Sunderland, MA, 2000).

Hoyer, M. Untersuchungen ueber das Lymphgefaessystem der Froschlarven. Bull. Acad. Cracov. Teill II, 451–464 (1905).